MX339692B - Moduladores de los receptores 5-ht y metodos de uso de los mismos. - Google Patents

Moduladores de los receptores 5-ht y metodos de uso de los mismos.

Info

Publication number
MX339692B
MX339692B MX2012012279A MX2012012279A MX339692B MX 339692 B MX339692 B MX 339692B MX 2012012279 A MX2012012279 A MX 2012012279A MX 2012012279 A MX2012012279 A MX 2012012279A MX 339692 B MX339692 B MX 339692B
Authority
MX
Mexico
Prior art keywords
octahydropyrazino
methods
compounds
modulators
receptors
Prior art date
Application number
MX2012012279A
Other languages
English (en)
Other versions
MX2012012279A (es
Inventor
W Djuric Stevan
Akritopoulou-Zanze Irini
Braje Wilfried
Wang Ying
T Brewer Jason
Pohlki Frauke
Relo Ana-Lucia
Original Assignee
Abbvie Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc * filed Critical Abbvie Inc *
Publication of MX2012012279A publication Critical patent/MX2012012279A/es
Publication of MX339692B publication Critical patent/MX339692B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
    • Y02E60/30—Hydrogen technology
    • Y02E60/32—Hydrogen storage

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente solicitud se refiere a derivados de 1 ,2,3,4)4a,5,6,7-octahidropirazino[1 ,2-a][1 ,4]benzodiacepina, 1, 2, 3, 4, 4a, 5, 6, 7-octahidropirazino[1)2-a][1 ,5jbenzodiazepina, 1, 2, 3, 4, 4a, 5, 6, 7, 11 b-octahidro-1 H-pirido[3,4-d(][2]benzazepina,1 ,2 ,3 ,4 ,4ª ,5 ,6 ,7-octahidropirazino[1 ,2-a][1]benzazepina, 1 ,2 ,3 ,4 ,4ª ,5-hexahidro-7H-pirazino[1 ,2-a][4, 1]benzoxazepina, y 2,3,4,4a,5,6- hexahidro-1 H-pirazino[2,l-d][1 ,5]benzoxazepina, y 5 ,6 ,7 ,7ª ,8,9 ,10, 11 -octahídropirazino[1 ,2-d]pirido[3,2-6][l ,4]diazepina de la fórmula (I) en la cual R1, R2, R3, R4, R5, R6, X1, X2, X3, X4, Y1, Y2, y Y3 son como se definen en la descripción. La presente solicitud también se refiere a composiciones que comprenden dichos compuestos, y a métodos para tratar condiciones patológicas utilizando dichos compuestos y composiciones, y a métodos para identificar dichos compuestos.
MX2012012279A 2010-04-22 2010-10-21 Moduladores de los receptores 5-ht y metodos de uso de los mismos. MX339692B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/765,034 US8518933B2 (en) 2009-04-23 2010-04-22 Modulators of 5-HT receptors and methods of use thereof
PCT/US2010/053530 WO2011133182A1 (en) 2010-04-22 2010-10-21 Modulators of 5-ht receptors and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2012012279A MX2012012279A (es) 2013-03-08
MX339692B true MX339692B (es) 2016-06-06

Family

ID=44834964

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2012012279A MX339692B (es) 2010-04-22 2010-10-21 Moduladores de los receptores 5-ht y metodos de uso de los mismos.
MX2016002648A MX347948B (es) 2010-04-22 2010-10-21 Moduladores de los receptores 5-ht y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2016002648A MX347948B (es) 2010-04-22 2010-10-21 Moduladores de los receptores 5-ht y metodos de uso de los mismos.

Country Status (8)

Country Link
US (4) US8518933B2 (es)
EP (2) EP2560973B1 (es)
JP (2) JP6049610B2 (es)
CN (2) CN105367578A (es)
CA (1) CA2797019C (es)
ES (1) ES2616087T3 (es)
MX (2) MX339692B (es)
WO (1) WO2011133182A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673896B2 (en) * 2010-04-22 2014-03-18 Abbvie Inc. Benzodiazepine and pyridodiazepine derivatives
HRP20251123T1 (hr) 2012-07-12 2025-11-21 Emalex Biosciences, Inc. Ekopipam za liječenje touretteovog sindroma
JP6041387B2 (ja) * 2013-03-27 2016-12-07 住友精化株式会社 一酸化窒素の品質維持方法
US9949983B2 (en) * 2013-10-18 2018-04-24 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of stuttering
US20180339996A1 (en) 2015-11-25 2018-11-29 AbbVie Deutschland GmbH & Co. KG Hexahydropyrazinobenz- or -pyrido-oxazepines carrying an oxygen-containing substituent and use thereof in the treatment of 5-ht2c-dependent disorders
EP3500570B1 (en) * 2016-08-19 2022-10-05 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2025194153A1 (en) 2024-03-15 2025-09-18 Emalex Biosciences, Inc. Pharmaceutical dosage forms and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328390A (en) * 1962-02-27 1967-06-27 Tri Kem Corp Certain azabicycloalkane compounds
US4082773A (en) * 1972-07-03 1978-04-04 E. R. Squibb & Sons, Inc. Tricyclic tetrahydro naphthaleneols and related compounds
GB1593146A (en) * 1976-11-05 1981-07-15 Beecham Group Ltd Octahydro-quinolizinyl benzamide derivatives
EP0126343A1 (en) 1983-05-18 1984-11-28 Beecham Group Plc Treatment of diarrhoea
DE3522959A1 (de) * 1985-06-27 1987-01-08 Merck Patent Gmbh Indolderivate
US5049637A (en) * 1987-04-10 1991-09-17 Monash University 1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino-[1,2-a]azepino derivatives and 10-aza, 10-oxa and 10-thia analogues
DE68926673T2 (de) 1988-12-15 1997-01-16 Abbott Lab 5-ht-selektive mittel
US5049564A (en) * 1989-11-17 1991-09-17 Abbott Laboratories 5-HT selective agents
US5071853A (en) 1989-03-23 1991-12-10 Bigge Christopher F Polycyclic amines useful as cerebrovascular agents
EP0389189B1 (en) 1989-03-23 1994-05-18 Pfizer Limited Diazepine antiallergy agents
US5244888A (en) * 1989-11-17 1993-09-14 Abbott Laboratories 5-HT selective agents
GB9014061D0 (en) * 1990-06-25 1990-08-15 Merck Sharp & Dohme Therapeutic agents
AU657793B2 (en) 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
ATE155143T1 (de) 1991-09-27 1997-07-15 Merrell Pharma Inc 2-substituierte indan-2-mercaptoacetylamid- verbindungen mit enkephalinase und ace- hemmwirkung
JPH07500333A (ja) 1991-10-24 1995-01-12 ジ・アップジョン・カンパニー ベンゾ−イソキノリン誘導体
PL310443A1 (en) * 1993-03-01 1995-12-11 Merck Sharp & Dohme Derivatives of pyrolo-pyridine
US5622950A (en) * 1993-03-01 1997-04-22 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
US5597922A (en) * 1994-07-29 1997-01-28 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon Glycine receptor antagonist pharmacophore
GB9507291D0 (en) * 1995-04-07 1995-05-31 Merck Sharp & Dohme Therapeutic agents
JPH09249570A (ja) 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ベンゾジアゼピン化合物含有ケモカイン受容体拮抗剤
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
US6649366B2 (en) 1999-12-29 2003-11-18 Smithkline Beecham Corporation Methods and compositions related to modulators of annexin and cartilage homeostasis
EP1406631A4 (en) 2001-06-13 2005-03-23 Univ Michigan DOPAMIN RECEPTOR LIGANDS AND THERAPEUTIC METHODS BASED THEREFOR
PL378120A1 (pl) * 2003-02-14 2006-03-06 Wyeth Heterocyklilo-3-sulfonyloindazole jako ligandy 5-hydroksytryptaminy
US20080146583A1 (en) * 2003-05-15 2008-06-19 Pfizer Inc Treatment of Incontinence
TW200524864A (en) * 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
WO2005087775A1 (ja) 2004-03-15 2005-09-22 Ono Pharmaceutical Co., Ltd. 三環式複素環化合物およびその化合物を有効成分として含有する医薬組成物
ATE381566T1 (de) * 2004-05-14 2008-01-15 Millennium Pharm Inc Verbindungen und verfahren zur inhibierung der mitotischen progression durch hemmung von aurorakinase
WO2005118591A1 (en) 2004-05-31 2005-12-15 Ranbaxy Laboratories Limited Condensed piperidine compounds acting as adrenergic receptor antagonists useful in the treatment of prostatic hyperplasia and lower urinary symptoms
KR101197672B1 (ko) 2004-08-30 2012-11-07 얀센 파마슈티카 엔.브이. 11-베타 하이드록시스테로이드 데하이드로게나제저해제로서 트리사이클릭 락탐 유도체
WO2006028961A2 (en) 2004-09-03 2006-03-16 Athersys, Inc. Tricyclic heteroaryl piperazines, pyrrolidines and azetidines as serotonin receptor modulators
TW200621677A (en) 2004-09-21 2006-07-01 Astellas Pharma Inc Cyclic amine derivative or salt thereof
WO2006125179A1 (en) 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
CN101291913A (zh) * 2005-08-15 2008-10-22 惠氏公司 作为5-羟色胺-6配体的吖嗪基-3-磺酰基吲唑衍生物
GB0517292D0 (en) 2005-08-24 2005-10-05 Univ Dundee Cell migration modulating compounds
PA8720901A1 (es) * 2006-03-24 2008-11-19 Wyeth Corp Tratamiento del dolor
CA2645099A1 (en) * 2006-03-24 2007-10-04 Wyeth Methods for modulating bladder function
WO2007115232A2 (en) 2006-03-30 2007-10-11 Chemocentryx, Inc. Cxcr4 modulators
RU2318818C1 (ru) 2006-04-12 2008-03-10 Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" Азагетероциклы, комбинаторная библиотека, фокусированная библиотека, фармацевтическая композиция и способ получения (варианты)
WO2008007661A1 (en) 2006-07-11 2008-01-17 Takeda Pharmaceutical Company Limited Tricyclic heterocyclic compound and use thereof
WO2008021038A2 (en) * 2006-08-09 2008-02-21 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
US8242105B2 (en) 2006-09-25 2012-08-14 Forschungsverbund Berlin E.V. Structural mimetics of proline-rich peptides and the pharmaceutical use thereof
FR2912145B1 (fr) * 2007-02-02 2009-03-06 Servier Lab Nouveaux derives tricycliques,leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TW200924752A (en) 2007-09-17 2009-06-16 Organon Nv Tricyclic heterocyclic derivatives
BRPI0908433A2 (pt) * 2008-02-06 2019-09-24 Novartis Ag pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
WO2010124042A2 (en) * 2009-04-23 2010-10-28 Abbott Laboratories Modulators of 5-ht receptors and methods of use thereof
FR2945754A1 (fr) * 2009-05-20 2010-11-26 Total Raffinage Marketing Nouveaux additifs pour huiles transmission

Also Published As

Publication number Publication date
CN102958932B (zh) 2015-11-25
EP3150607A1 (en) 2017-04-05
ES2616087T3 (es) 2017-06-09
JP2013525350A (ja) 2013-06-20
JP6049610B2 (ja) 2016-12-21
EP2560973B1 (en) 2016-11-16
US9701679B2 (en) 2017-07-11
MX347948B (es) 2017-05-19
US8518933B2 (en) 2013-08-27
US20180127423A1 (en) 2018-05-10
EP2560973A4 (en) 2013-09-04
CA2797019A1 (en) 2011-10-27
WO2011133182A1 (en) 2011-10-27
CN102958932A (zh) 2013-03-06
MX2012012279A (es) 2013-03-08
US20100273767A1 (en) 2010-10-28
JP2016040249A (ja) 2016-03-24
US20130310368A1 (en) 2013-11-21
CA2797019C (en) 2018-03-20
CN105367578A (zh) 2016-03-02
US8846663B2 (en) 2014-09-30
US20150175611A1 (en) 2015-06-25
EP2560973A1 (en) 2013-02-27

Similar Documents

Publication Publication Date Title
WO2010124042A3 (en) Modulators of 5-ht receptors and methods of use thereof
TN2011000247A1 (en) Organic compounds
MY152386A (en) Substituted 6a,7,8,9-tetrahydropyrido[3,2-e] pyrrolo[1,2-a]pyrazin-6(5h)-ones
MX2009010728A (es) Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora.
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
NZ703111A (en) Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
MX347948B (es) Moduladores de los receptores 5-ht y metodos de uso de los mismos.
MX358682B (es) Derivados de pirazolo [1,5a]pirimidina y de tieno[3,2b] pirimidina como moduladores de la cinasa asociada al receptor de la interleucina 4 (irak4).
EA201170769A1 (ru) Органические соединения
NZ594567A (en) 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
GEP20135780B (en) Novel pyrazolo [3,4-d] pyrimidine derivatives as anti-cancer agents
EA201290147A1 (ru) Пирроло[2,3-d]пиримидиновые соединения
UA99459C2 (en) 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
NZ603792A (en) Modulators of 5-ht receptors and methods of use thereof
NZ598743A (en) Substituted dihydro benzocycloalkyloxymethyl oxazolopyrimidinones, preparation and use thereof
ZA201304646B (en) 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
MX2011008452A (es) Derivados de triazolo [4,3-b] piridazina y sus usos para el cancer de prostata.
PL2024368T3 (pl) Pochodne 6,7,8,9-tetrahydro-5H-pirymido[4,5-d]azepin-4-ylo]-aminy jako modulatory TRPV1 do leczenia bólu
MY152283A (en) Polo-like kinase inhibitirs
AU2011325479A8 (en) 7-([1,2,3]Triazol-4-yl)-pyrrolo[2,3-b]pyrazine derivatives
EP2549874A4 (en) SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
MY183111A (en) 3-(heteroaryl-amino)-1,2,3,4-tetrahydro-9h-carbazole derivatives and their use as prostaglandin d2 receptor modulators
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
WO2010011546A3 (en) Pyrrolo [3, 2-b]pyridines and pyrazolo [4, 3 -b] pyridines having 5-ht6 receptor affinity
MX2008011576A (es) Compuestos de imidazo[2,1-b]tiazol sustituidos y su uso para la produccion de farmacos.

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.*

FG Grant or registration